Cortexyme

Cortexyme

Verified
Cortexyme is developing novel treatments for altering the course of Alzheimer's and other neurological diseases

Launch date
Employees
Ownership
Market cap
$58.3m
Net debt
-
Firm valuation
$304—456m (Public information from May 2018)
San Francisco California (HQ)
Deals in current and previous year:

Financials

Edit
  • Edit
DateInvestorsAmountRound
-N/A-
Not yet verified
N/AN/AGrant
$1mSeed
$15mSeries A
$7.6mDebt
$76mSeries B
N/AN/AIPO
N/A$125mPost IPO Equity
Not yet verified
Total Funding$92m

Recent News about Cortexyme

Edit

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.

Investments by Cortexyme

Edit
Novosteo
ACQUISITION by Cortexyme May 2022